Search

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor in adults. The etiology of GBM is not known, and the prognosis is usually very poor. Despite new diagnostic techniques and treatment methods, the management of patients with GBM is difficult. Currently, the standard of care for the treatment of GBM is surgical resection, followed by concurrent RT with temozolomide, completed by adjuvant CT with temozolomide. Despite the survival benefit associated with these treatments, the majority of patients relapse following initial therapy. Unfortunately, optimal management for patients with recurrent or progressive GBM is unclear. In general, treatment for recurrent GBM may involve repeated resection, focal irradiation, and systemic therapies. When considering in terms of chemotherapy regimen, bevacizumab and irinotecan combination therapy for the progressive GBM may be used a suitable regimen. Also complete response in case of recurrent GBM is very rare. We present two cases with GBM who had complete response with bevacizumab plus irinotecan as second-line CT regimen, which rapidly progressed after surgery, chemoradiotherapy (CRT) and first-line temozolomide therapy. Signs of rapid proliferation in the pathologic specimen of both cases were recorded. During follow-up both cases developed recurrent tumor within a month after first three cycles first-line temozolomide CT.

Bimetallic nanoparticles (NP) have improved properties such as antimicrobial, anticancer and photocatalytic activity due to the synergistic effects of their components. Unmet needs of the current cancer treatments encourage researchers for the new treatment approaches especially natural products. In this study, we aimed to investigate the antiproliferative effects of Ag@ZnO NP on the SH-SY5Y human neuroblastoma cell line. Ag@ZnO NP was dispersed in distilled water via ultrasonication and diluted with the medium as the 5, 10, 25, 50, 100, 200 and 400 μg/mL final concentrations. The cell viabilities were investigated by MTT test at 24th hours of Ag@ZnO NP treatments. In MTT test, the lower concentrations of Ag@ZnO NP (5, 10, 25 μg/mL) increased the cell viability (p < 0.01, p < 0.01 and p < 0.05, respectively) whereas it was markedly decreased (p < 0.001) the cell viabilities at higher concentrations (100, 200 and 400 ug/ml) compared with the control group. Our results showed that Ag@ZnO NP has antiproliferative effects on SH-SY5Y cells whereas it increases cell proliferation in the low dose. The effects in the low dose may depend on its activation of compensatory mechanisms in the cell. We have thought that it is worthwhile to research its anticancer potential on the different cancer cell lines.

Objective:Port catheterization, which can be practically applied by various clinical and surgical branches in our country, is an extremely comfortable procedure in patient groups requiring long-term parenteral treatment, especially malignancy patients.Method:In this study, 156 patients who underwent port catheterization by an anesthesiologist after the approval of the local ethics committee were evaluated retrospectively.Results:The procedure was performed in 98.1% of the patients due to malignancy (originated esophagus: 37.3%, stomach: 24.8%). The most common application part was the right internal jugular vein (65.4%). Sixty-two patients required two or more punctures. Port was removed due to port pocket infection in 1.9% of the patients.Conclusion:In this study, we presented our port catheterization experience and aimed to contribute to the national literature.